Oxford Immunotec's T-SPOT®.TB Test Included in the World Health Organization's First-Ever Essential Diagnostics List
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 21, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that the Company's T-SPOT.TB test for tuberculosis (TB) infection has been included in the World Health Organization (WHO) Model List of Essential In Vitro Diagnostics (EDL) - First Edition.
The EDL includes the 113 most important tests recommended by WHO for use at various levels of the health care system. These essential diagnostics satisfy the priority health care needs of the population and were selected with due regard to disease prevalence and public health relevance, evidence of efficacy and accuracy, and comparative cost-effectiveness. 58 of the tests listed are for the detection and diagnosis of a wide range of common conditions, providing an essential package that can form the basis for screening and management of patients. The remaining 55 tests are designed for the detection, diagnosis, and monitoring of WHO key disease areas, for which there is high quality evidence - HIV, tuberculosis (TB), malaria, hepatitis B and C, syphilis and human papilloma virus. Included in the list were interferon-gamma release assays, of which Oxford Immunotec's T-SPOT.TB test is one of two available globally.
"Despite steady progress in reducing the burden of tuberculosis in recent decades, TB remains a major global health problem and one of the top 10 causes of death worldwide," said Dr. Richard Wenstrup, Chief Medical Officer of Oxford Immunotec. "As acknowledged in the February 2018 publication of new WHO guidelines1, the identification and management of LTBI in people with a high risk of developing active TB is a critical component of the WHO End TB Strategy. We applaud the inclusion of IGRAs in the WHO's EDL and are pleased to see further recognition of the important role IGRAs will play in the global fight against TB."
1 Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, and intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.
Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
For Media and Investor Inquiries:
Head of Strategy and Investor Relations
Tel: +1 (508) 556-1377
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
PRESS RELEASE: BIGBEN INTERACTIVE: 1ST QUARTER SALES OF 58.6 M€ UP 20.3 %22.7.2019 18:00:00 CEST | Press release
Press Release Lesquin, 22 July 2019 18:00 1st quarter sales of 58.6 M€ up 20.3 % Strong rise of Gaming (+27.3%) Increase of Current Operating Profit rate for FY 2019/20 now set in excess of 10% IFRS – M€ Sales Non audited data 2019/2020 2018/2019 Change 1st Quarter Of which Gaming Of which Mobile Of which Audio 58.6 29.9 23.1 5.5 48.7 23.5 21.1 4.1 + 20.3% + 27.3% + 9.7% + 34.5% Strong growth in Gaming in Q1 2019/20 In the first quarter of FY 2019/20 (April to June 2019), Bigben achieved sales of 58.6 M€, a 20.3% increase. GAMING The Gaming business recorded a 27.3% growth in Q1 2019/20 with 29.9 M€ sales. Publishing: The shift from the business model towards more digital sales accelerated in Q1 2019/20 with an increase exceeding 250% in this distribution channel. This channel now accounts for more than two-thirds of revenues. The releases of Warhammer®: Chaosbane, The Sinking City, Tennis World Tour® Roland Garros Edition, Pro Cycling Manager 2019 and Tour de France® 2019 also contrib
EVS Broadcast Equipment reports update of share buyback program22.7.2019 17:45:00 CEST | Press release
Publication on July 22, 2019, 5.45pm CET Regulated information – reporting share buyback EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports update of share buyback program EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on October 24, 2018, took place between July 15, 2019 and July 17, 2019. Date Number of shares acquired Average price (EUR) Total (EUR) 15/07/2019 1,856 20.3713 37,809 16/07/2019 1,760 20.0932 35,364 17/07/2019 378 20.9000 7,900 As of July 22, 2019, and since the start of the buyback program, EVS has bought 255,028 shares at an average price of EUR 20.8174, representing in total EUR 5,309,024. After aforementioned transactions the total number of own shares amounts now to 333,676 shares as of July 22, 2019 (including 93,144 shares already held by the company before the start of the share buyback program and taking into account t
Change in Amer Sports Corporation’s financial reporting schedule22.7.2019 17:15:00 CEST | Press release
Amer Sports Corporation STOCK EXCHANGE RELEASE July 22, 2019 at 6:15 p.m. Change in Amer Sports Corporation’s financial reporting schedule Amer Sports changes the publication date of its half-year financial report 2019. The updated schedule for the half-year report is 30 September, 2019 at approximately 1:00 p.m. Finnish time. The previously announced publication date was July 25, 2019. The change is related to the recent ownership change in the company. ANTA Sports Products Limited consolidates Amer Sports as an associated company in its half-year financial report which will be published on 26 August, 2019. On the same day, Amer Sports will publish a stock exchange release disclosing its financial information included in ANTA Sports’ half-year financial report. On March 28, 2019, Mascot Bidco Oy completed a voluntary recommended public cash tender offer for all the issued and outstanding shares in Amer Sports Corporation and on April 1, 2019 announced that it will exercise its redempt
Changes in Huhtamaki’s Global Executive team22.7.2019 17:00:00 CEST | Press release
HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 22.7.2019 AT 18:00 Changes in Huhtamaki’s Global Executive team Michael Orye, Executive Vice President, Fiber Packaging and a member of Huhtamaki Global Executive Team has decided to leave Huhtamaki to pursue other career opportunities. Eric Le Lay, Executive Vice President Foodservice EAO will assume the leadership and take full responsibility of Fiber Packaging in addition to his current role. This change is effective as of 22.7.2019. “I want to thank Michael for his contribution to Huhtamaki and wish him all success in his future endeavors” says Charles Héaulmé, President and CEO of Huhtamaki. Following the aforementioned change, the members of the Global Executive Team are: Charles Héaulmé (chairman), President and CEO Thomas Geust, Chief Financial Officer; Leena Lie, Senior Vice President, Marketing and Communications; Sami Pauni, Senior Vice President, Corporate Affairs and Legal, Group General Counsel; Teija Sarajärvi, Senior Vice President,
Banks net position in the Riksbank22.7.2019 16:42:00 CEST | Press release
JUL 22, 2019 SEK MILLION LENDING BORROWING 281
Metso establishes a new business services center in Vilnius22.7.2019 14:00:00 CEST | Press release
Metso establishes a new business services center in Vilnius Metso Corporation’s press release on July 22, 2019 at 15:00 EEST Metso has decided to establish a new Metso Business Services (MBS) center in Vilnius, the capital of Lithuania. The investment supports the company’s profitable growth strategy by improving operational excellence and scalability of business services. The Vilnius MBS center will initially offer services for Metso’s finance operations, later followed by logistics. The objective is to centralize the related services to the new center and thus gain benefits from process harmonization, standardization and digitalization. Initially, the center will employ some tens of experts, but the number of personnel is expected to grow in the coming years. As part of the initiative, employee negotiations have been held at Metso Minerals in Tampere, Finland, to review the possible employee arrangements and implications. Metso has decided to transfer its Financial Services operation